NCT06092125 Clinical Applicantion of Multi-Tracer PET/MR Imaging in Neurological Disorders/Disease
| NCT ID | NCT06092125 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Xuanwu Hospital, Beijing |
| Condition | Alzheimer Disease |
| Study Type | OBSERVATIONAL |
| Enrollment | 2,300 participants |
| Start Date | 2022-10-01 |
| Primary Completion | 2025-10-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 2,300 participants in total. It began in 2022-10-01 with a primary completion date of 2025-10-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The goal of this clinical trial is to learn about the application of domestic PET/MR in major brain diseases. The main questions it aims to answer are: * Overcome the bottleneck of early accurate diagnosis and treatment in major brain diseases clinical practice. * Promote the clinical application of domestic PET/MR, enhance international competitiveness. Participants will have a PET/MR scan of the brain.
Eligibility Criteria
Inclusion Criteria: 1. Patients diagnosed with mild cognitive impairment (MCI) or Alzheimer's disease (AD), rapid eye movement sleep behavior disorder (RBD) or Parkinson's disease (PD), epilepsy, malignant brain tumors based on clinical guidelines. 2. Patients admitted to our hospital for inpatient treatment. Exclusion Criteria: 1. Patients who have undergone non-invasive/minimally invasive treatments such as radiotherapy or chemotherapy within the past three weeks. And Patients who have taken Alzheimer's disease-related and Parkinson's disease-related treatment drugs within the past month. 2. Patients with persistent seizures or status epilepticus that cannot be controlled by medication, resulting in an inability to cooperate with the examination. 3. patients with poorly controlled blood sugar and ineffective medication intervention. 4. Patients with absolute contraindications for PET/MR examination. 5. Karnofsky Performance Score (KPS) \<60.
Contact & Investigator
Jie Lu, Phd
PRINCIPAL INVESTIGATOR
Xuanwu Hospital of Capital Medical University
Frequently Asked Questions
Who can join the NCT06092125 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 60 Years, studying Alzheimer Disease. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06092125 currently recruiting?
Yes, NCT06092125 is actively recruiting participants. Contact the research team at imaginglu@hotmail.com for enrollment information.
Where is the NCT06092125 trial being conducted?
This trial is being conducted at Beijing, China.
Who is sponsoring the NCT06092125 clinical trial?
NCT06092125 is sponsored by Xuanwu Hospital, Beijing. The principal investigator is Jie Lu, Phd at Xuanwu Hospital of Capital Medical University. The trial plans to enroll 2,300 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.